SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-19-054651
Filing Date
2019-10-17
Accepted
2019-10-18 15:23:33
Documents
1
Group Members
VERSANT AFFILIATES FUND V, L.P.VERSANT OPHTHALMIC AFFILIATES FUND I, L.P.VERSANT V LUXCO S.A.R.L.VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURE CAPITAL V (CANADA) LPVERSANT VENTURE CAPITAL V, L.P.VERSANT VENTU

Document Format Files

Seq Description Document Type Size
1 SC 13G a19-20435_1sc13g.htm SC 13G 378061
  Complete submission text file 0001104659-19-054651.txt   380017
Mailing Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 650-233-2215
Versant Ventures V, LLC (Filed by) CIK: 0001619298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Subject) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91159 | Film No.: 191157633
SIC: 2834 Pharmaceutical Preparations